Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company decreased its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 23.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 31,225 shares of the company’s stock after selling 9,790 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.11% of Krystal Biotech worth $5,684,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Segall Bryant & Hamill LLC increased its position in shares of Krystal Biotech by 352.4% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company’s stock worth $28,605,000 after purchasing an additional 122,407 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of Krystal Biotech by 1,972.0% during the second quarter. Principal Financial Group Inc. now owns 123,469 shares of the company’s stock valued at $22,674,000 after acquiring an additional 117,510 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Krystal Biotech by 115.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company’s stock valued at $35,583,000 after acquiring an additional 103,928 shares during the period. Public Sector Pension Investment Board purchased a new stake in shares of Krystal Biotech in the 2nd quarter valued at approximately $10,037,000. Finally, Rhumbline Advisers lifted its holdings in shares of Krystal Biotech by 123.3% in the 2nd quarter. Rhumbline Advisers now owns 71,685 shares of the company’s stock worth $13,164,000 after acquiring an additional 39,586 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on KRYS. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. Evercore ISI increased their target price on Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research note on Monday, August 12th. Stifel Nicolaus raised their target price on Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Citigroup boosted their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Finally, William Blair raised shares of Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $202.29.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the transaction, the insider now owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. This represents a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 14.10% of the company’s stock.

Krystal Biotech Stock Performance

Shares of KRYS opened at $179.76 on Friday. Krystal Biotech, Inc. has a 1 year low of $100.98 and a 1 year high of $219.34. The stock has a market capitalization of $5.17 billion, a PE ratio of 101.56 and a beta of 0.80. The stock has a 50-day simple moving average of $181.10 and a 200-day simple moving average of $184.26.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same quarter in the previous year, the firm earned ($0.67) earnings per share. The firm’s quarterly revenue was up 879.9% on a year-over-year basis. Analysts predict that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).